The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isATX-304 is O304 (AdisInsight lists O304 as another name for it), so its human data is O304's: a 28-day randomized, double-blind, placebo-controlled phase IIa in 65 people with type 2 diabetes already on metformin (Steneberg 2018, JCI Insight 3(12):e99114).
- What to watchPalpitations or breathlessness on mild exertion.
How ATX-304 works
Direct pan-AMPK activator — flips the cellular energy switch toward fat oxidation and glucose uptake, an exercise-mimetic small molecule.
AMPK is not one enzyme. It is a heterotrimer — a catalytic α subunit, a scaffolding β subunit and a nucleotide-sensing γ subunit — and with two α, two β and three γ genes there are 12 mammalian complexes, expressed in different proportions in different tissues Myers 2017.
Physiologically, AMPK reads the adenylate charge: AMP and ADP bind the γ subunit's CBS domains, and phosphorylation of Thr172 on the α subunit by LKB1 or CaMKK2 switches the kinase on. This molecule does not skip that step: as O304 it keeps the phosphorylated Thr172 from being removed — the step ADP normally guards — and it needs LKB1 to have done its part first Steneberg 2018. It still reports an energy deficit that has not happened.
- Oral
On the goal map: AMPK activation & cellular fuel sensing (Metabolic health & insulin sensitivity)
Research on ATX-3046 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Early human (phase IIa, as O304) + animal.
Human clinical evidence
ATX-304 is O304 (AdisInsight lists O304 as another name for it), so its human data is O304's: a 28-day randomized, double-blind, placebo-controlled phase IIa in 65 people with type 2 diabetes already on metformin (Steneberg 2018, JCI Insight 3(12):e99114). Fasting plasma glucose and HOMA-IR fell, peripheral microvascular perfusion improved, blood pressure came down, and it was well tolerated.
The developer has also reported a phase 1b, as a conference poster (American Diabetes Association 86th Scientific Sessions, poster 1782-P, June 2026). That is conference data, not a peer-reviewed paper. The peer-reviewed trial measured glucose control over 28 days, not fat loss or performance.
Correlative data
Almost no research-market presence and no practical record to report. That absence is worth stating plainly rather than filling with extrapolation from other AMPK activators.
How the mechanism reads
A pan-AMPK activator that acts on AMPK itself rather than through the cell's energy charge. Metformin activates AMPK by inhibiting complex I and raising the AMP:ATP ratio; AICAR mimics AMP. As O304 it was shown to keep the activated enzyme switched on by blocking its dephosphorylation; where it binds has not been published.
MechanisticThat makes it an amplifier more than a switch: it needs the upstream kinase LKB1 and raises AMPK activity only in cells where some is already present. No dependence on mitochondrial inhibition, and no independence from what the cell is already doing either.
MechanisticSame mTOR tension as AICAR — sustained AMPK activation opposes protein synthesis, which is the predicted cost for anyone using it alongside training.
Mechanistic
Sources
- Katerelos M, Gleich K, Harley G, Loh K, Oakhill JS, Kemp BE, de Souza DP, Narayana VK, Coughlan MT, Laskowski A, Ling NXY, Murray-Segal L, Brink R, Lee M, Power DA, Mount PF. The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury. Biomed Pharmacother 2024 · PMID 38749175
- Holm E, Vermeulen I, Parween S, Lopez-Perez A, Cillero-Pastor B, Vandenbosch M, Remeseiro S, Hornblad A. AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching. JCI Insight 2025 · PMID 40197369
- Myers RW, Guan HP, Ehrhart J, Petrov A, Prahalada S, Tozzo E, Yang X, Kurtz MM, Trujillo M, Gonzalez Trotter D, Feng D, Xu S, Eiermann G, Holahan MA, Rubins D, Conarello S, Niu X, Souza SC, Miller C, Liu J, Lu K, Feng W, Li Y, Painter RE, Milligan JA, He H, Liu F, Ogawa A, Wisniewski D, Rohm RJ, Wang L, Bunzel M, Qian Y, Zhu W, Wang H, Bennet B, LaFranco Scheuch L, Fernandez GE, Li C, Klimas M, Zhou G, van Heek M, Biftu T, Weber A, Kelley DE, Thornberry N, Erion MD, Kemp DM, Sebhat IK. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy.. Science 2017 · PMID 28705990
- Steneberg P, Lindahl E, Dahl U, Lidh E, Straseviciene J, Backlund F, Kjellkvist E, Berggren E, Lundberg I, Bergqvist I, Ericsson M, Eriksson B, Linde K, Westman J, Edlund T, Edlund H. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients.. JCI Insight 2018 · PMID 29925691
ATX-304 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Known heart disease or arrhythmia, since related pan-AMPK activators raised cardiac glycogen and heart size in animals.
- Type 1 diabetes or insulin use, where extra glucose uptake can tip into hypoglycemia.
- Active cancer, because AMPK activation alters tumor energy handling both ways.
- Pregnancy or breastfeeding, since AMPK drive alters fetal energy handling.
- Liver impairment, as the phase 2a safety record is only 28 days.
What’s expected
- Improved insulin sensitivity and glucose uptake in muscle.
- A shift of fuel use toward fat oxidation.
- Mild gut upset in short phase 1 and 2a studies.
Watch for
- Palpitations or breathlessness on mild exertion.
- Sweating, shakiness or confusion, the low glucose pattern.
- Ankle swelling.
Labs that tell you it’s working
- HbA1c: the glucose-lowering endpoint for an exercise-mimetic.
- Insulin (Fasting): shows whether sensitivity improved without extra insulin.
- Lipid Panel: fat oxidation should lower triglycerides.
- High-Sensitivity Troponin T: the cardiac safety read for the AMPK-class heart signal.
Direct pan-AMPK activator (O304); metabolic gain from AMPK drive, with an unresolved cardiac question from the pan-activator class. PMID 29925691 PMID 28705990
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
ATX-304 FAQ4 common questions
- Is ATX-304 approved for human use?
- No. ATX-304 is a research compound.
- What is ATX-304 researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- HbA1c; Insulin; Lipid Panel; High-Sensitivity Troponin T: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for ATX-304: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.





